Susceptibility of human T cell leukemia virus type 1 to reverse-transcriptase inhibitors:: Evidence for resistance to lamivudine

被引：34

作者：

García-Lerma, JG ^{[1
]}

Nidtha, S ^{[1
]}

Heneine, W ^{[1
]}

机构：

[1] CDCP, HIV & Retrovirol Branch, Div AIDS STD & TB Lab Res, Natl Ctr Infect Dis, Atlanta, GA 30333 USA

来源：

JOURNAL OF INFECTIOUS DISEASES | 2001年 / 184卷 / 04期

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1086/322785

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Nucleoside reverse-transcriptase (RT) inhibitors (NRTIs), including lamivudine (3TC) and zidovudine (Zdv), are being evaluated for the treatment of human T cell lymphotropic virus type 1 (HTLV-1)-associated disease. However, information on the susceptibility of HTLV-1 to these drugs is limited. The activity of 5 NRTIs on HTLV-1 RT was evaluated. IC50 values for Zdv, zalcitabine (ddC), didanosine (ddI), 3TC, and stavudine (d4T) were determined, using an enzymatic assay, for 5 HTLV-1 isolates and for reference wild-type and NRTI-resistant human immunodeficiency virus type 1 (HIV-1). Both HTLV-1 and wild-type HIV-1 were equally susceptible to Zdv, ddC, ddI, and d4T. In contrast, high-level resistance to 3TC was found in all HTLV-1 isolates. The findings support the clinical use of Zdv, ddC, ddI, and d4T but not of 3TC for the antiretroviral treatment of HTLV-1-associated disease.

引用

页码：507 / 510

页数：4

共 15 条

[1] CHARACTERIZATION OF HUMAN T-LYMPHOTROPIC VIRUS TYPE I-INFECTED AND II-INFECTED T-CELL LINES - ANTIGENIC, PHENOTYPIC, AND GENOTYPIC ANALYSIS [J].

DEZZUTTI, CS ;

RUDOLPH, DL ;

ROBERTS, CR ;

LAL, RB .

VIRUS RESEARCH, 1993, 29 (01) :59-70

[2] Wild-type and YMDD mutant murine leukemia virus reverse transcriptases are resistant to 2′,3′-dideoxy-3′-thiacytidine [J].

Halvas, EK ;

Svarovskaia, ES ;

Freed, EO ;

Pathak, VK .

JOURNAL OF VIROLOGY, 2000, 74 (14) :6669-6674

[3] A rapid non-culture-based assay for clinical monitoring of phenotypic resistance of human immunodeficiency virus type 1 to lamivudine (3TC) [J].

Lerma, JGG ;

Schinazi, RF ;

Juodawlkis, AS ;

Soriano, V ;

Lin, YL ;

Tatti, K ;

Rimland, D ;

Folks, TM ;

Heneine, W .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (02) :264-270

[4] AZT inhibits the transmission of human T cell leukaemia/lymphoma virus type I to adult peripheral blood mononuclear cells in vitro [J].

Macchi, B ;

Faraoni, I ;

Zhang, J ;

Grelli, S ;

Favalli, C ;

Mastino, A ;

Bonmassar, E .

JOURNAL OF GENERAL VIROLOGY, 1997, 78 :1007-1016

[5]

Machuca A, 2000, J ACQ IMMUN DEF SYND, V24, P189

[6] Human T-lymphotropic virus type I infection [J].

Manns, A ;

Hisada, M ;

La Grenade, L .

LANCET, 1999, 353 (9168) :1951-1958

[7] PHARMACOLOGICAL INHIBITION OF INVITRO INFECTIVITY OF HUMAN LYMPHOTROPIC-T VIRUS TYPE-I [J].

MATSUSHITA, S ;

MITSUYA, H ;

REITZ, MS ;

BRODER, S .

JOURNAL OF CLINICAL INVESTIGATION, 1987, 80 (02) :394-400

[8] Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP [J].

Nagai, M ;

Usuku, K ;

Matsumoto, W ;

Kodama, D ;

Takenouchi, N ;

Moritoyo, T ;

Hashiguchi, S ;

Ichinose, M ;

Bangham, CRM ;

Izumo, S ;

Osame, M .

JOURNAL OF NEUROVIROLOGY, 1998, 4 (06) :586-593

[9] Therapeutic trials in 200 patients with HTLV-I-associated myelopathy/tropical spastic paraparesis [J].

Nakagawa, M ;

Nakahara, K ;

Maruyama, Y ;

Kawabata, M ;

Higuchi, I ;

Kubota, H ;

Izumo, S ;

Arimura, K ;

Osame, M .

JOURNAL OF NEUROVIROLOGY, 1996, 2 (05) :345-355

[10] ELEVATED ANTIBODIES TO SYNTHETIC PEPTIDES OF HTLV-1 ENVELOPE TRANSMEMBRANE GLYCOPROTEINS IN PATIENTS WITH HAM TSP [J].

NAKAMURA, M ;

KUROKI, M ;

KIRA, J ;

ITOYAMA, Y ;

SHIRAKI, H ;

KURODA, N ;

WASHITANI, Y ;

NAKANO, S ;

NAGAFUCHI, S ;

ANZAI, K ;

TATSUMOTO, T ;

ESAKI, T ;

MAEDA, Y ;

NIHO, Y .

JOURNAL OF NEUROIMMUNOLOGY, 1991, 35 (1-3) :167-177

← 1 2 →